Pacific Biosciences Of California (PACB) Receivables (2010 - 2026)

Pacific Biosciences Of California's Receivables history runs 17 years deep, the most recent figure standing at $29.4 million for Q1 2026.

• On a quarterly basis, Receivables fell 7.25% year-over-year to $29.4 million in Q1 2026; TTM through Mar 2026 was $29.4 million, a 7.25% decrease from a year earlier, with the FY2025 full-year figure at $35.4 million, up 28.79% from the prior year.
• Receivables declined to $29.4 million in Q1 2026 per PACB's latest filing, from $35.4 million in the prior quarter.
• Across five years, Receivables topped out at $36.6 million in Q4 2023 and bottomed at $18.8 million in Q4 2022.
• The 5-year median for Receivables is $29.6 million (2023), against an average of $29.2 million.
• Across the five-year window, Receivables soared 115.81% in 2022 and declined 24.83% in 2024, its largest moves.
• Year by year, Receivables stood at $18.8 million in 2022, then surged by 94.91% to $36.6 million in 2023, then slipped by 24.83% to $27.5 million in 2024, then grew by 28.79% to $35.4 million in 2025, then declined by 17.2% to $29.4 million in 2026.
• Per Business Quant, the three latest PACB Receivables figures stand at $29.4 million (Q1 2026), $35.4 million (Q4 2025), and $30.6 million (Q3 2025).